Challenges for biomarkers in cancer detection

Annals of the New York Academy of Sciences

Volumn 1022, Issue , 2004, Pages 9-16

  Wagner, Paul D ^a   Verma, Mukesh ^a   Srivastava, Sudhir ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Cancer detection

Indexed keywords

BIOLOGICAL MARKER;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CONFERENCE PAPER; GENE IDENTIFICATION; GENOMICS; HUMAN; PROTEOMICS; UNITED STATES;

EID: 3242709363     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1318.003     Document Type: Conference Paper

References (17)

1. ETZIONI, R., N. URBAN, S. RAMSEY, et al. 2003. The case for early detection. Nat. Rev. Cancer 3: 243-252.
2. PEPE, S.M., R. ETZIONI, Z. FENG, et al. 2001. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93: 1054-1061.
3. VERMA, M., J. KAGAN, D. SIDRANSKY & S. SRIVASTAVA. 2003. Proteomic analysis of cancer-cell mitochondria. Nat. Rev. Cancer 3: 789-795.
4. ALLANDER, S.V., P.E. ILLEI, Y. CHEN, et al. 2002. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am. J. Pathol. 161: 1587-1595.
5. HA, P.K., T.A. PILKINGTON, W.H. WESTRA, et al. 2002. Progression of microsatellite instability from premalignant lesions to tumors of the head and neck. Int. J. Cancer 102: 615-617.
6. HOQUE, M.O., J. LEE, S. BEGUM, et al. 2003. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res. 63: 5723-5726.
7. AHLQUIST, D.A. & A.P. SHUBER. 2002. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin. Chim. Acta 315: 157-168.
8. QU, Y., B.L. ADAM, Y. YASUI, et al. 2002. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin. Chem. 48: 1835-1843.
9. PETRICOIN, E.F., A.M. ARDEKANI, B.A. HITT, et al. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577.
10. YE, B., D.W. CRAMER, S.J. SKATES, et al. 2003. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9: 2904-2911.
11. BRICHORY, F., D. BEER, F. LE NAOUR, et al. 2001. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 61: 7908-7912.
12. O'BRIEN, N., T.M. MAGUIRE, N. O'DONOVAN, et al. 2002. Mammaglobin a: a promising marker for breast cancer. Clin. Chem. 48: 1362-1364.
13. MARRERO, J.A., G.L. SU, W. WEI, et al. 2003. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 37: 1114-1121.
14. VERMA, M., B.K. DUNN, S. ROSS, et al. 2003. Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention. Ann. N.Y. Acad. Sci. 983: 298-319.
15. VERMA, M. & S. SRIVASTAVA. 2002. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol. 3: 755-763.
16. KAWAKAMI, K., J. BRABENDER, R. V. LORD, et al. 2000. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 92: 1805-1811.
17. VERMA, M. & S. SRIVASTAVA. 2003. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res. 163: 72-84; discussion 264-266.